Corresponding Author: Jennifer A. Doudna, PhD, 2151 Berkeley Way, Berkeley, CA 94704 (firstname.lastname@example.org).
Conflict of Interest Disclosures: Dr Kan reported being a fellow in the Pediatric Scientist Development Program, supported by award K12-HD000850 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr Doudna reported being a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences; serving as a scientific advisory board member for Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, and Inari; being a director at Johnson & Johnson; and having research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche. In addition, Dr Doudna had a patent for CRISPR-Cas9 issued.
M , Chylinski
K , Fonfara
et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science
. 2012;337(6096):816-821. PubMedGoogle ScholarCrossref
JM , Pierce
AJ , Oh
et al. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol
. 2004;24(21):9305-9316. PubMedGoogle ScholarCrossref
Locatelli F, Frangoul H, Corbacioglu S, et al. Efficacy and safety of a single dose of CTX001 for transfusion-dependent beta-thalassemia and severe sickle cell disease
. June 12, 2022. https://bit.ly/3Ak5Ao4